Investors are reassessing opportunities in kidney disease therapies, driven by new delivery strategies and regulatory clarity. ProKidney and Nephrogen's CEOs highlight the potential for commercially viable products in a historically challenging market.

A recent case report highlights the co-occurrence of aortic dissection and polycystic kidney disease, suggesting a potential link between these conditions. This discovery may prompt further research into their relationship and implications for patient management.

OMass’s molecule is vying to become an alternative to a Neurocrine Biosciences drug that is currently the only FDA-approved therapy for congenital adrenal hyperplasia. But Vertex Pharmaceuticals could also compete with a drug candidate from a recent acquisition. By Lisa Brooks, Vice President, Healthcare Partnerships · Here’s a recap of other recent life sciences financing activity: —Estuary Biotherapeutics launched, revealing $103 million in funding for two gene therapies in development for autosomal dominant polycystic kidney disease (ADPKD), an inherited progressive disorder that leads to the growth of cysts on the kidneys. An undisclosed private family fund and foundation led BrainChild’s Series A round. —Moonwalk Biosciences raised $70 million as it looks to bring obesity drug candidate MW101 into the clinic next year. The South San Francisco- and San Diego-based biotech develops small-interfering RNA that is delivered to adipose tissue to precisely modulate pathways that are different than the ones addressed by GLP-1 drugs. But Vertex Pharmaceuticals could also compete with a drug candidate from a recent acquisition. ... OMass Therapeutics now has $310 million in financing to support a pipeline led by a drug in development for a rare endocrine disorder with limited treatment options. The disease is congenital adrenal hyperplasia (CAH), an inherited condition in which patients lack an enzyme the adrenal glands need to produce key hormones. This drug came from Vertex’s recently closed $10 billion acquisition of Crinetics Pharmaceuticals. OMass’s new capital will support plans to bring OMS1620 through Phase 2 testing in CAH and ACTH-dependent Cushing’s syndrome. The Series C round announced on Oct. 15 will also support OMass’s earlier-stage assets. A drug the company describes as a potential first-in-class SLC15A4 inhibitor is in development for lupus and other diseases associated with interferon overproduction and pathogenic B-cell activation.

Estuary Biotherapeutics is seeking to address the root cause of autosomal dominant polycystic kidney disease with two gene therapy programs based on science from Yale.

Roche and Ionis Pharmaceuticals' RNA therapy, sefaxersen, demonstrated a reduction in protein levels in urine during late-stage testing, indicating potential improvements in kidney function. This progress may expedite FDA approval for the treatment of kidney disease.